scholarly journals 2-(3,4-Dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol

Molbank ◽  
10.3390/m1144 ◽  
2020 ◽  
Vol 2020 (3) ◽  
pp. M1144 ◽  
Author(s):  
Alessandra Gianoncelli ◽  
Alberto Ongaro ◽  
Giuseppe Zagotto ◽  
Maurizio Memo ◽  
Giovanni Ribaudo

On the basis of the knowledge from traditional herbal and folk medicine, flavonoids are among the most studied chemical classes of natural compounds for their potential activity as phosphodiesterase 5 (PDE5) inhibitors. We here describe the preparation of a semi-synthetic hydrazone derivative of quercetin, 2-(3,4-dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol, that was obtained via a single-step modification of the natural compound. The product was characterized by NMR, mass spectrometry and HPLC. Preliminary molecular modeling studies suggest that this compound could efficiently interact with PDE5.

2013 ◽  
Vol 78 (1-4) ◽  
pp. 437-443 ◽  
Author(s):  
Joanna Biernacka ◽  
Katarzyna Betlejewska-Kielak ◽  
Janina Witowska-Jarosz ◽  
Ewa Kłosińska-Szmurło ◽  
Aleksander P. Mazurek

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Ashraf H. Abadi ◽  
Jochen Lehmann ◽  
Gary A. Piazza ◽  
Mohammad Abdel-Halim ◽  
Mohamed S. M. Ali

Two series of fused tetrahydro-β-carboline hydantoin and tetrahydro-β-carboline thiohydantoin derivatives with a pendant 2,4-dimethoxyphenyl at position 5 were synthesized, and chiral carbons at positions 5 and 11a swing from R,R to R,S, S,R, and S,S. The prepared analogues were evaluated for their capacity to inhibit phosphodiesterase 5 (PDE5) isozyme. The R absolute configuration of C-5 in the β-carboline hydantoin derivatives was found to be essential for the PDE5 inhibition. Chiral carbon derived from amino acid even if of the S configuration (L-tryptophan) may lead to equiactive or more active isomers than those derived from amino acid with the R configuration (D-tryptophan). This expands the horizon from which efficient PDE5 inhibitors can be derived and may offer an economic advantage. The thiohydantoin derivatives were less active than their hydantoin congeners.


2006 ◽  
Vol 1115 (1-2) ◽  
pp. 118-124 ◽  
Author(s):  
Emmanuel Bissé ◽  
Nathalie Zorn ◽  
Stéphanie Boussert ◽  
Thomas Epting ◽  
Alain Van Dorsselaer ◽  
...  

2012 ◽  
Vol 402 (9) ◽  
pp. 2737-2748 ◽  
Author(s):  
Marija Brgles ◽  
Branimir Bertoša ◽  
Wolfgang Winkler ◽  
Tihana Kurtović ◽  
Günter Allmaier ◽  
...  

Author(s):  
Nikolaos Sofikitis ◽  
Aris Kaltsas ◽  
Fotios Dimitriadis ◽  
Jens Rassweiler ◽  
Nikolaos Grivas ◽  
...  

The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate a role of PDE5 inhibitors in the regulation of sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.


Sign in / Sign up

Export Citation Format

Share Document